// App-Quantinova.ai

THU0311 (2018) : Impact of secukinumab treatment on psoriatic arthritis patients with or without enthesitis at baseline: pooled data from two phase 3 studies (FUTURE 2 AND FUTURE 3

Researchers

Presenter

  • J.K. Wallman

Principal Investigators

  • G. Schett

  • I.B. McInnes

  • E. Quebe-Fehling

  • L. Rasouliyan

  • L. Pricop

  • A.E. Fasth

  • C. Gaillez

Medical Centers

  • Lund University Hospital, Lund, Sweden

  • University of Erlangen-Nuernberg, Erlangen, Germany

  • EScience, University of Glasgow, Glasgow, UK

  • Novartis AG, Basel, Switzerland

  • RTI Health Solutions, Barcelona, Spain

  • Novartis Pharmaceutical Corporation, East Hanover, NJ

  • Novartis Sverige AB, Kista, Sweden

Locations

  • Sweden

  • Germany

  • United Kingdom

  • Switzerland

  • Spain

  • United States

Companies

  • RTI Health Solutions

Study Components

Therapeutic Area

  • Dermatology

  • Musculoskeletal

Disease

  • Psoriatic arthritis

Biomarkers

  • N/A

Drug/Treatment

  • secukinumab

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • III

Study Id's

  • NCT01752634

  • NCT01989468

Sponsors

  • BMS Infotech

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved